N-tert-butyl-4,4-dimethylpent-1-en-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-tert-butyl-4,4-dimethylpent-1-en-2-amine
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: FUHQMEBWXZBYBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE TRITERPÈNE EN TANT QU'INHIBITEURS DU VIH
  申请人：HETERO LABS LTD

  公开号：WO2020165741A1

  公开（公告）日：2020-08-20

  The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

  本发明涉及公式（I）的新型三萜衍生物；及其药学上可接受的盐，其中R1、R2、R3、R4和环如本文所定义。该发明还涉及新型三萜衍生物、相关化合物和药物组合物，用于治疗病毒性疾病，特别是HIV介导的疾病。
• Linker Compound, Polyethylene Glycol-Linker Conjugate and Derivative Thereof and Polyethylene Glycol-Linker-Drug Conjugate
  申请人：JENKEM TECHNOLOGY CO., LTD. (TIANJIN)

  公开号：US20200289655A1

  公开（公告）日：2020-09-17

  The disclosure discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker-drug conjugate. The linker compound as well as the conjugate thereof with the polyethylene glycol and the derivative thereof may be used for modifying a drug, and a modification reaction is simple and easy to carry out. Moreover, a reaction yield is high, and an application range of the modified drug is wide. The modified drugs gradually degrade from a chain of the conjugate in vivo, and may stay in a lesion (such as a cancer site) for a longer period of time, achieving purposes of sustained and controlled release, reducing an administration frequency, and greatly improving a bioavailability of the drug and a patient compliance.

  该披露揭示了一种连接剂化合物，聚乙二醇连接剂共轭物及其衍生物，以及聚乙二醇连接剂药物共轭物。连接剂化合物以及其与聚乙二醇的共轭物和衍生物可用于修饰药物，修饰反应简单易行。此外，反应产率高，改性药物的应用范围广泛。修饰后的药物在体内逐渐从共轭链中降解，并可在病变部位（如癌症部位）停留更长时间，实现持续和受控释放的目的，减少给药频率，大大提高药物的生物利用度和患者依从性。
• DIPEPTIDES AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES
  申请人：CORNELL UNIVERSITY

  公开号：US20170121366A1

  公开（公告）日：2017-05-04

  The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R 1 -R 10 , X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由以下具有式（I）的化合物表示，其中取代基R1-R10、X、Y、k、m、n、q和s的定义如本文所述。这些化合物用于治疗癌症、免疫紊乱、自身免疫性疾病、神经退行性疾病或炎症性疾病，或用于为移植的器官或组织提供免疫抑制。
• Rab7 GTPase Inhibitors and Related Methods of Treatment
  申请人：Wandinger-Ness Angela

  公开号：US20140248268A1

  公开（公告）日：2014-09-04

  This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.

  本发明涉及化合物及其作为Rab7 GTP酶抑制剂或激活剂的用途，以治疗或预防Rab 7 GTP酶相关疾病，如神经病变、癌症、骨代谢疾病和脂质储存病。该发明还适用于Rab7被失活或其蛋白质-蛋白质相互作用被调节以促进病原体的细胞内生存的感染性疾病。所述化合物作为核苷酸结合的竞争性抑制剂，并且也具有作为靶向其他小GTP酶的支架的效用。在一个方面，本发明的治疗方法用于治疗或预防遗传性感觉神经病变，如Charcot-Marie-Tooth 2B病。还提供相关的制药组合物、测定和药物筛选。
• Nitrobenzyl derivatives of anti-cancer agents
  申请人：OBI PHARMA, INC.

  公开号：US11535585B2

  公开（公告）日：2022-12-27

  Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

  本文提供了式 I.的化合物，其中变量在本文中定义： 其中的变量在本文中定义，还提供了制造这些化合物的工艺，以及通过施用这些化合物治疗癌症的方法。